Somnomed Limited · ASX:SOM
Somnomed — Investor Presentation (September 2010)
16 slides from Somnomed's investor presentation, Sep 2, 2010
Slide 1: Review FY 2009-10 Investor Presentation September 2010
For personal use only Review FY 2009 - 10 Investor Presentation September 2010 This presentation contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are not guarantees of SomnoMed's future performance and involve a number of risks and uncertaint
Slide 2: The World's #1 Oral Sleep Appliance Company
The World’s # 1 For personal use only Oral Sleep Appliance Company Vision Improving health and quality of life through better breathing and sleep Mission Global leadership in Dental Sleep Medical offering evidence based, non-invasive, innovative solutions advancing the treatment of sleep-disordered
Slide 3: SomnoMed - Global Operations
For personal use only SomnoMed® - Global Operations SomnoMed Manufacturing Dedicated Approved, > 45,000 OSA operates in 20 in 12 locations team of 68 certified, patients in countries with with 9 license personnel in 8 listed: TGA, treatment in 20 subsidiaries in partners and 3 countries FDA, CE,ISO
Slide 4: Third Generation Treatment Option
For personal use only Third Generation Treatment Option PATENTED – CLINICALLY PROVEN – COMPLIANT OSA TREATMENT Investor Presentation September 2010 4
Slide 5: Highlights FY 09/10 vs. FY 08/09
For personal use only Highlights FY 09/10 vs. FY 08/09 • Sales revenue increased by 38% to A$10.7 m • Unit sales increased by 60% to 19,543 devices • Group operating profit of A$1.8m before Corporate/R&D • EBITDA improved for full year to A$ 0.27 m from A$ (1.52 m) • Strong balance sheet – no debt,
Slide 6: Financial Results
For personal use only Financial Results Financial Summary ( $000's ) 09/10 08/09 07/08 06/07 Units 19,543 12,254 7,033 3,503 Revenue 10,714 7,737 3,658 2,273 Gross Margin 6,084 4,059 1,956 1,002 Operating profit / ( loss) before corporate, 1,842 19 (933) (1,588) business development and non cash ite
Slide 7: North America-Europe-APAC Drive Volume Growth
North America-Europe-APAC For personal use only Drive Volume Growth Units sold per quarter Unit contribution per region est. FY 09/10 CAGR Units 67% 16% USA 16% 68% AUS EU Investor Presentation September 2010 7
Slide 8: Strong Growth in Revenue and Gross Margin
Strong Growth in Revenue and For personal use only Gross Margin SomnoMed® Progress CAGR Revenue 56% GM improvement from 52% to 57% in 2010 Investor Presentation September 2010 8
Slide 9: Outlook FY 10-11
For personal use only Outlook FY 10-11 Performance & Innovation Investor Presentation September 2010 9
Slide 10: Objectives and Strategic Tasks FY 10/11
Objectives and Strategic For personal use only Tasks FY 10/11 • Sales revenue > A$ 15 m • Apnea unit sales >28,000 • Bruxism unit sales > 2,000 • Positive EBITDA • Expansion of the global SomnoMed Dental Network > 3,000 • Breakthrough product innovations to be launched in 2011: • The world’s first P
Slide 11: Global Medicare Awareness
For personal use only Global Medicare Awareness Sweden - 1995 Medicare Japan - 2003 Medicare Oral Appliance Treatment USA - 2006 (Medicare reimbursement expected 2010) accepted and recommended for France - 2008 Medicare mild to moderate OSA and CPAP Belgium - 2009 Medicare non-compliance: Germany -
Slide 12: Opportunity & Challenge
For personal use only Opportunity & Challenge Investor Presentation September 2010 12
Slide 13: Strategic Alliances, Research & Innovation
Strategic Alliances, Research & For personal use only Innovation Strategic Alliances to develop the medical market with Insurance Companies, Sleep Clinics and Home Sleep Test providers Clinical Research projects in Australia, Germany, Israel, Italy, US Broadening of product line and emphasis on prod
Slide 14: Continued Growth expected
For personal use only Continued Growth expected it y r tun po op wth gr o ra ted le ce Ac Investor Presentation September 2010 14
Slide 15: Review SomnoMed - The future is now
For personal use only Review SomnoMed®… The future is now... Thank-you Investor Presentation September 2010 15
Slide 16: Contacts
For personal use only Contacts: Chairman Dr Peter Neustadt Chief Executive Officer Mr Ralf Barschow Address Level 3, 20 Clarke Street Crows Nest NSW 2065 Australia Telephone +61 (0)2 9467 0400 Website www.somnomed.com.au 16